» Articles » PMID: 15035283

Convection-enhanced Delivery of Paclitaxel for the Treatment of Recurrent Malignant Glioma: a Phase I/II Clinical Study

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2004 Mar 24
PMID 15035283
Citations 136
Authors
Affiliations
Soon will be listed here.
Abstract

Object: A minority of patients with recurrent glioblastomas multiforme (GBMs) responds to systemic chemotherapy. The authors investigated the safety and efficacy of intratumoral convection-enhanced delivery (CED) of paclitaxel in patients harboring histologically confirmed recurrent GBMs and anaplastic astrocytomas.

Methods: Fifteen patients received a total of 20 cycles of intratumoral CED of paclitaxel. The patients were observed daily by performing diffusion-weighted (DW) magnetic resonance (MR) imaging to assess the convective process and routine diagnostic MR imaging to identify the tumor response. Effective convection was determined by the progression of the hyperintense signal within the tumor on DW MR images, which corresponded to a subsequent lytic tumor response displayed on conventional MR images. Of the 15 patients, five complete responses and six partial responses were observed, giving a response rate of 73%. The antitumor effect was confirmed by one biopsy and three en bloc resections of tumors, which showed a complete response, and by one tumor resection, which demonstrated a partial response. Lack of convection and a poor tumor response was associated with leakage of the convected drug into the subarachnoid space, ventricles, and cavities formed by previous resections, and was seen in tumors containing widespread necrosis. Complications included transient chemical meningitis in six patients, infectious complications in three patients, and transient neurological deterioration in four patients (presumably due to increased peritumoral edema).

Conclusions: On the basis of our data we suggest that CED of paclitaxel in patients with recurrent malignant gliomas is associated with a high antitumor response rate, although it is associated with a significant incidence of treatment-associated complications. Diffusion-weighted MR images may be used to predict a response by demonstrating the extent of convection during treatment. Optimization of this therapeutic approach to enhance its efficacy and reduce its toxicity should be explored further.

Citing Articles

Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment.

Giantini-Larsen A, Pandey A, Garton A, Rampichini M, Winston G, Goldberg J Neurooncol Adv. 2025; 7(1):vdae201.

PMID: 39877748 PMC: 11773386. DOI: 10.1093/noajnl/vdae201.


A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.

Narsinh K, Kumar K, Bankiewicz K, Martin A, Berger M, Clarke J J Neurooncol. 2025; 172(1):219-227.

PMID: 39760796 PMC: 11832582. DOI: 10.1007/s11060-024-04904-y.


Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.

Holdhoff M, Ye X, Strowd R, Nabors B, Walbert T, Lieberman F Neurooncol Adv. 2024; 6(1):vdae150.

PMID: 39371261 PMC: 11450402. DOI: 10.1093/noajnl/vdae150.


A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma.

Rolfe N, Dadario N, Canoll P, Bruce J Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204078 PMC: 11357193. DOI: 10.3390/ph17080973.


A Self-Cascade Penetrating Brain Tumor Immunotherapy Mediated by Near-Infrared II Cell Membrane-Disrupting Nanoflakes via Detained Dendritic Cells.

Yalamandala B, Chen Y, Lin Y, Huynh T, Chiang W, Chou T ACS Nano. 2024; 18(28):18712-18728.

PMID: 38952208 PMC: 11256899. DOI: 10.1021/acsnano.4c06183.